Redsense Medical AB announces today that an evaluation programme is launching in the Netherlands to test a new version of the Redsense Alarm, with additional functionality that has been developed in response to clinical experiences – a direct connection for the unit into the nurse call system of the clinic. The evaluation will comprise 100-150 treatments and is expected to be completed during the fall of 2020. The evaluation programme is conducted in collaboration with the Company’s distributor in the region, Dirinco.
“This new product has been developed in response to a request from a clinic. We are happy to be able to explore this new opportunity and we are eager to enhance the alarm solution, and to assist the clinics in finding the best possible ways to implement the Redsense Alarm for optimal patient safety,” says Redsense Medical’s CEO Patrik Byhmer.
The new alarm unit is effectively a modified version of the already well established Redsense Alarm. With the new nurse call connection, the alarm will go off as usual, but in addition, a signal will also be sent through the clinical unit’s nurse call system (NCS) to ensure that the alarm is acknowledged by the attending healthcare professionals as promptly as possible. The evaluation programme will consist of about 100-150 treatments, and Redsense Medical expects to have the results ready during the fall.
“This is a small scale evaluation which purely focuses on testing the nurse call connection in a clinical setting,” explains Sebastien Bollue, Director Commercial Operations at Redsense Medical: “We are pleased to carry out the evaluation programme together with our local distributor Dirinco with whom we have a great and well-established relationship and previously worked together on evaluating the PAS alarm unit in a reference clinic before it was rolled out in the Netherlands on a larger scale.”
Dirinco BV has been Redsense’s distributor in the Netherlands since 2018, and offers the Company’s alarm system together with hemodialysis machines from Redsense collaboration partners Nikkiso and NxStage. The Netherlands, where more than 6,000 patients are depending on dialysis, is one of the important European markets. Dirinco BV has over 30 years of experience in the market and sells products developed inhouse as well as products from other manufacturers.